A study to compare Biochip and direct immunofluorescence in diagnosis of autoimmune bullous diseases.
Not Applicable
- Conditions
- Health Condition 1: L123- Acquired epidermolysis bullosaHealth Condition 2: L120- Bullous pemphigoidHealth Condition 3: L128- Other pemphigoidHealth Condition 4: L102- Pemphigus foliaceousHealth Condition 5: L100- Pemphigus vulgaris
- Registration Number
- CTRI/2019/03/018032
- Lead Sponsor
- P Arunprasath
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
All new cases of autoimmune bullous disease.
Autoimmune bullous disease patients under treatment with active disease.
Exclusion Criteria
Autoimmune bullous disease Patients in clinical remission
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To find out whether biochip can be used as a routine diagnostic technique in the diagnosis of autoimmune bullous skin diseases by comparing with an already existing gold standard method direct immunofluorescence.Timepoint: 1 year
- Secondary Outcome Measures
Name Time Method Autoimmune bullous skin disorders showing floor binding in salt split skin could be further evaluated using target antigen study and further typified into rare pemphigoid variants like Anti-p200 pemphigoid, Laminin 332 pemphigoid.Timepoint: 1 year